Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

The Human Tumor Atlas Network charts the roadmap for advancing spatial omics

The NCI Human Tumor Atlas Network (HTAN) has published a cluster of papers intended to advance the framework of spatial omics, the science of profiling morphological and molecular features of human cancers in two and three dimensions.

AI test is equivalent to Oncotype DX at predicting breast cancer recurrence, study shows

COTA Inc., PreciseDx, and Baptist Health South Florida announced study results validating that the artificial intelligence-enabled PreciseBreast test is equivalent to the Oncotype DX test at predicting breast cancer recurrence. The research was presented at the San Antonio Breast Cancer Symposium.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Genetic disposition increases the risk of breast cancer metastasis

For over 50 years, scientists have been on a quest to identify which malignant mutations within the tumor allow rogue cells to break away from the primary tumor and travel through the bloodstream and lymphatic system to metastasize throughout the body. Now, new research suggests an alternative mechanism has been overlooked—elusive mutations driving metastasis may not be developing within the twisted DNA of tumors themselves, but within the patient’s regular, inherited DNA.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Genetic mutations accumulate in smokers with MDS, study shows

Smokers with myelodysplastic syndromes or a precursor condition had elevated levels of genetic mutations linked to the disease, a new study shows. The study also found that heavier smokers accumulated more mutations, and long-term smokers were more likely to show disease progression.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Study identifies that higher West African ancestry may contribute to worse outcomes

A study published in JAMA Network Open underscored the importance of utilizing genetic ancestry beyond self-reported race in prognosticating breast cancer outcomes for Black women and addressing their disproportionately higher mortality rate.

December 13, 2024

Vol.50 No.46

In Brief

Siemens Healthineers, Ohio State Wexner Medical Center form 10-year, $105M partnership

Siemens Healthineers and The Ohio State Wexner Medical Center have expanded their existing strategic relationship to form a 10-year, $105 million value partnership to foster breakthroughs in clinical care, in addition to their longstanding research collaboration.

December 06, 2024

Vol.50 No.45

Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

YOU MAY BE INTERESTED IN

The Human Tumor Atlas Network charts the roadmap for advancing spatial omics

AI test is equivalent to Oncotype DX at predicting breast cancer recurrence, study shows

Genetic disposition increases the risk of breast cancer metastasis

Genetic mutations accumulate in smokers with MDS, study shows

Study identifies that higher West African ancestry may contribute to worse outcomes

Siemens Healthineers, Ohio State Wexner Medical Center form 10-year, $105M partnership

Renew today!

Subscriber content

Never miss an issue!

Login